Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 29 tags : Topline save search
Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe COVID-19 ARDS: Topline 60-Day Results From Randomized Controlled Trial
Published: 2021-04-29 (Crawled : 00:00) - globenewswire.com
MESO | $5.97 7.96% 7.37% 630K
|
Health Technology
|
| O: 4.02%
H: 19.71%
C: 2.0%
covid results topline trial
Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Published: 2021-04-29 (Crawled : 15:00) - biospace.com/
CARA | $0.7097 -2.83% -2.92% 180K
|
Health Technology
|
| O: -43.48%
H: 11.0%
C: -3.47%
phase 2 results dermatitis topline trial atopic dermatitis
Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans
Published: 2021-04-29 (Crawled : 14:15) - biospace.com/
PSTI | $1.0 -2.91% 8.0%
|
Health Technology
|
| O: 10.84%
H: 0.99%
C: -13.77%
positive results topline
Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021
Published: 2021-04-29 (Crawled : 13:15) - biospace.com/
CANF | $1.97 -0.51% 0.0% 3.8K
|
Health Technology
|
| O: 1.83%
H: 0.45%
C: -1.35%
results topline psoriasis enroll
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.